Gary Phillips has been named president and CEO of San Francisco-based OrphoMed. Phillips comes to OrphoMed from Mallinckrodt Pharmaceuticals (NYSE: [[ticker:MNK]]) where he was executive vice president and chief strategy officer. With the Phillips hire, OrphoMed’s founder, Nikhilesh Singh, is taking on the newly created position of chief scientific officer. OrphoMed’s lead drug, ORP-101, is in Phase 1 studies testing it as a treatment for irritable bowel syndrome with diarrhea.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
